We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Oncorus Inc
7 own
8 watching
Current Price
$0.43
$0.03
(7.45%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
11.16M
52-Week High
3.68
52-Week Low
0.23
Average Volume
0.23M
Dividend Yield
--
P/E Ratio
--
Market Capitalization11.16M52-Week High3.6852-Week Low0.23Average Volume0.23MDividend Yield--P/E Ratio--What does the Oncorus Inc do?
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company s lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Oncorus Inc make?
News & Events about Oncorus Inc.
Globe Newswire
2 months ago
ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate ...
Globe Newswire
2 months ago
ONCR-719 is uniquely engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry, which is highly expressed in glioblastoma multiforme (GBM); data show that the canonical entry receptor for HSV-1, NECTIN-1, is only minimally expressed in human GBM tumors. ONCR-719 ...
Globe Newswire
3 months ago
New preclinical results support self-amplifying vRNA/LNP immunotherapy platform and ongoing IND-enabling studies of ONCR-021ANDOVER, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on stimulating the immune system to transform outcomes ...
Globe Newswire
9 months ago
ONCR-021 and ONCR-788 demonstrate robust preclinical anti-tumor efficacy following IV-administration vRNA Immunotherapy Platform has the potential to address challenges associated with IV-administered RNA-based oncology therapeutics Oncorus is advancing ONCR-021 into clinical development, with IND ...
Zolmax
10 months ago
HC Wainwright assumed coverage on shares of Oncorus (NASDAQ:ONCR Get Rating) in a research report released on Monday morning, The Fly reports. The brokerage issued a buy rating and a $7.00 target price on the stock. A number of other analysts have also commented on the company. Zacks Investment ...
Frequently Asked Questions
Frequently Asked Questions
What is Oncorus Inc share price today?
Can Indians buy Oncorus Inc shares?
How can I buy Oncorus Inc shares from India?
Can Fractional shares of Oncorus Inc be purchased?
What are the documents required to start investing in Oncorus Inc stocks?
What is today’s traded volume of Oncorus Inc?
What is today’s market capitalisation of Oncorus Inc?
What is the 52-Week High and Low Range of Oncorus Inc?
What percentage is Oncorus Inc down from its 52-Week High?
What percentage is Oncorus Inc up from its 52-Week Low?
Current Price
$0.43
$0.03
(7.45%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.